Subscribe

ASCO 2014 - Lung Cancer

The value of prophylactic cranial irradiation (PCI) in decreasing the incidence of brain metastases in patients with NSCLC has been demonstrated, but a new study presented at ASCO 2014 examined the impact of PCI on survival...
Two presentations at ASCO 2014 examined the value of postoperative adjuvant erlotinib in patients with completely resected Stage IA/B-IIIA NSCLC harboring a tyrosine kinase inhibitor–sensitizing EGFR mutation.
Cisplatin-based chemotherapy plus concurrent radiotherapy (RT) represent the current standard for unresectable, locally advanced NSCLC, but long-term overall survival (OS) in these patients is poor...
AP26113 is a novel, orally active tyrosine kinase inhibitor with activity against ALK and crizotinib-resistant mutants. This agent was tested in 106 patients with advanced ALK+ NSCLC who progressed on crizotinib therapy...
In a presentation at ASCO 2014, PD-L1 expression was evaluated in a series of adenocarcinomas (AD) and squamous cell carcinomas (SQ) of the lung.
Finally, a great deal of excitement was generated over data with nivolumab, an anti-PD-1 immune checkpoint inhibitor that has shown efficacy in melanoma and is now showing promise in non-small-cell lung cancer (NSCLC).
Results of clinical studies with several agents directed at novel molecular targets were also featured. Lenvatinib is an oral tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1-4, RET, KIT, and PDGFR-B.
Today’s ASCO presentations in non-small-cell lung cancer (NSCLC) also featured results from trials with existing agents and exciting data with new molecular entities.
While genomic-oriented and molecular biomarker research is interesting and has practice-changing potential.
This first day of in-depth presentations on non-small-cell lung cancer (NSCLC) kicked off with presentations on next-generation EGFR—tyrosine kinase inhibitors (TKIs) tested in patients who develop resistance to first-line EGFR inhibitor therapy due to T790M mutations (which occurs in ~40% of Asian patients and ~15% of Western patients with NSCLC and for which there are no approved treatments).
Page 2 of 3
Results 11 - 20 of 21
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology